Genetic predictors of plasma lipid response to diet intervention

Current Atherosclerosis Reports

Volumn 1, Issue 3, 1999, Pages 196-203

  Ordovas, Jose M ^a   Galluzzi, Jennifer R ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Arterioscler Thromb Vasc Biol; Cholesterol Ester Transfer Protein; Fatty Acid Binding; Postprandial Lipemia; Retinyl Palmitate

Indexed keywords

APOLIPOPROTEIN; CARRIER PROTEIN; CHOLESTEROL 7ALPHA MONOOXYGENASE; FABP2 PROTEIN, HUMAN; FABP2 PROTEIN, MOUSE; FABP7 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN; LIPID; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTERIOSCLEROSIS; BLOOD; DIET; FAT INTAKE; GENETIC PREDISPOSITION; GENETICS; HUMAN; LIPID METABOLISM; METABOLISM; REVIEW;

APOLIPOPROTEINS; ARTERIOSCLEROSIS; CARRIER PROTEINS; CHOLESTEROL 7-ALPHA-HYDROXYLASE; DIET; DIETARY FATS; FATTY ACID-BINDING PROTEINS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIPID METABOLISM; LIPIDS; NEOPLASM PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 0033224198     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-999-0032-8     Document Type: Article

References (65)

1. Ordovas JM, Schaefer EJ: Genes, variation of cholesterol and fat intake and serum lipids. Curr Opin Lipidol 1999, 10:15–22. DOI: 10.1097/00041433-199902000-00004
2. Ordovas JM: The genetics of serum lipid responsiveness to dietary interventions. Proc Nutr Soc 1999, 58:171–187. DOI: 10.1079/PNS19990023
3. Ordovas JM, Schaefer EJ: Treatment of dyslipidemia: genetic interactions with diet and drug therapy. Current Atherosclerosis Reports 1999, 1:16–23.
4. Rainwater DL, Kammerer CM, Hixson JE, et al.: Two major loci control variation in beta-lipoprotein cholesterol and response to dietary fat and cholesterol in baboons. Arterioscler Thromb Vasc Biol 1998, 18:1061–1068.
5. Blaauwwiekel EE, Beusekamp BJ, Sluiter WJ, et al.: Apolipoprotein E genotype is a determinant of low-density lipoprotein cholesterol and of its response to a low-cholesterol diet in type 1 diabetic patients with elevated urinary albumin excretion. Diabet Med 1998, 15:1031–1035. DOI: 10.1002/(SICI)1096-9136(1998120)15:12<1031::AID-DIA705>3.0.CO;2-6
6. Banaszak L, Winter N, Xu Z, et al.: Lipid-binding proteins: a family of fatty acid and retinoid transport proteins. Adv Protein Chem 1994, 45:89–151.
7. Sweetser DA, Birkenmeier EH, Klisak IJ, et al.: The human and rodent intestinal fatty acid binding protein genes. A comparative analysis of their structure, expression and linkage relationships. J Biol Chem 1987, 262:16060–16071.
8. Bernlohr DA, Simpson MA, Hertzel AV, Banaszak L: Intracellular lipid-binding protein and their genes. Annu Rev Nutr 1997, 17:277–303. DOI: 10.1146/annurev.nutr.17.1.277
9. Besnard P: Cellular and molecular aspects of fat metabolism in the small intestine. Proc Nutr Soc 1996, 55:19–37. DOI: 10.1079/PNS19960009
10. Van Nieuwenhoven FA, Van der Vusse GJ, Glatz JFC: Membrane-associated and cytoplasmic fatty acid-binding proteins. Lipids 1996, 31 (Suppl):S223-S227.
11. Bass NM, Manning JA, Ockner RK, et al.: Regulation of the biosynthesis of two distinct fatty acid binding proteins in the rat liver and intestine. J Biol Chem 1985, 260:1432–1436.
12. Ockner RK, Manning JA: Fatty acid binding protein in small intestine: identification, isolation and evidence for its rol in cellular fatty acid binding transport. J Clin Invest 1974, 54:326–338.
13. Sacchettini JC, Gordon JI, Banaszak L: Crystal structure of rat intestinal fatty acid-binding protein. Refinement and analysis of the E. coli-derived protein with bound palmitate. J Mol Biol 1989, 208:327–339 DOI: 10.1016/0022-2836(89)90392-6
14. Hodsdon ME, Cistola DP: Discrete backbone disorder in the nuclear magnetic resonance structure of intestinal fatty acid-binding protein: implications for the mechanism of ligand entry. Biochemistry 1997, 36:1450–1460. DOI: 10.1021/bi961890r
15. Baier LJ, Sacchettini JC, Knowler WC, et al.: An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance. J Clin Invest 1995, 95:1281–1287.
16. Schroeder F, Jolly CA, Cho T, Frolov A: Fatty acid binding isoforms: structure and function. Chem Phys Lipids 1998, 92:1–25. DOI: 10.1016/S0009-3084(98)00003-6
17. Hegele RA, Harris SB, Hanley AJ, et al.: Genetic variation of intestinal fatty acid binding protein associated with variation in body mass in aboriginal Canadians. J Clin Endocrinol Metab 1996, 81:4334–4337. DOI: 10.1210/jc.81.12.4334
18. Yagi T, Nishi S, Hinata SI, et al.: A population association study of four candidate genes (hexokinase II, glucagon-like peptide-1 receptor, fatty acid binding protein-2 and apolipoprotein C-II) with type 2 diabetes and impaired glucose tolerance in Japanese subjects. Diabet Med 1996, 13:902–907. DOI: 10.1002/(SICI)1096-9136(199610)13:10<902::AID-DIA242>3.0.CO;2-O
19. Vionnet N, Hani E, Lesage A, et al.: Genetics of NIDDM in France: studies with 19 candidate genes in affected sib pairs. Diabetes 1997, 46:1062–1068. DOI: 10.2337/diabetes.46.6.1062
20. Saarinen L, Pulkkinen A, Kareinen A, et al.: Variants of the fatt acid binding protein 2 gene are not associated with coronary heart disease in non diabetic subjects and in patients with NIDDM. Diabetes Care 1998, 21:849–850. DOI: 10.2337/diacare.21.5.849
21. Hegele RA, Young TK, Connell PW: Are Canadian Inuit at increased genetic risk for coronary heart disease? J Mol Med 1997, 75:364–370. DOI: 10.1007/s001090050122
22. Yamada K, Yuan X, Ishiyama S, et al.: Association between Ala54Thr substitution of the fatty acid binding protein 2 gene with insulin resistance and intra-abdominal fat thickness in Japanese men. Diabetologia 1997, 40:706–710. DOI: 10.1007/s001250050737
23. Pihlajamaki J, Rissanen J, Heikkinen S, et al.: Codon 54 polymorphism of the human intestinal fatty acid binding protein 2 gene is associated with dyslipidemias but not with insulin resistance in patients with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1997, 17:1039–1044.
24. Rissanen J, Pihlajamäki J, Heikkinen S, et al.: The Ala54Thr polymorphism of the fatty acid binding protein 2 gene does not influence insulin sensitivity in Finnish nondiabetic and NIDDM subjects. Diabetes 1997, 46:711–712.
25. Stern MP, Mitchell BD, Blangero J, et al.: Evidence for a major gene for type II diabetes and linkage analyses with selected candidate genes in Mexican-Americans. Diabetes 1996, 45:563–568. DOI: 10.2337/diabetes.45.5.563
26. Hegele RA, Connell PW, Hanley AJ, et al.: Common genomic variants associated with variation in plasma lipoproteins in young aboriginal Canadians. Arterioscler Thromb Vasc Biol 1997, 17:1060–1066.
27. Vidgren HM, Sipilainen RH, Heikkinen S, et al.: Threonine allele in codon 54 of the fatty acid binding protein 2 gene does not modify the fatty acid composition of serum lipids in obese subjects. Eur J Clin Invest 1997, 27:405–408. DOI: 10.1046/j.1365-2362.1997.1320679.x
28. Hegele RA, Wolever TM, Story A, et al.: Intestinal fatty acid binding protein variation associated with variation in the response of plasma lipoproteins to dietary fibre. Eur J Clin Invest 1997, 27:857–862 DOI: 10.1046/j.1365-2362.1997.2010748.x
29. Baier LJ, Bogardus C, Sacchettini JC: A polymorphism in the human intestinal fatty acid binding protein alters fatty acid transport across Caco-2 cells. J Biol Chem 1996, 271:10892–10896. DOI: 10.1074/jbc.271.20.11689
30. Prows DR, Murphy EJ, Moncecchi D, Schroeder F: Intestinal fatty acid binding protein expression stimulates fibroblast fatty acid esterification. Chem Phys Lipids 1996, 84:47–56. DOI: 10.1016/S0009-3084(96)02619-9
31. Corsico B, Cistola DP, Frieden C, Storch J: The helical domain of intestinal fatty acid binding protein is critical for collisional transfer of fatty acids to phospholipid membranes. Proc Natl Acad Sci U S A 1998, 95:12174–12178. DOI: 10.1073/pnas.95.21.12174
32. Richieri GV, Low PJ, Ogata RT, Kleinfeld AM. Thermodynamics of fatty acid binding to engineered mutants of the adipocyte and intestinal fatty acid binding proteins. J Biol Chem 1998, 273:7397–7405. DOI: 10.1074/jbc.273.13.7397
33. Zhang F, Lucke C, Baier LJ, et al.: Solution structure of human intestinal fatty acid binding protein: implications for ligand entry and exit. J Biomol NMR 1997, 9:213–228. DOI: 10.1023/A:1018666522787
34. Hodsdon ME, Cistola DP: Ligand binding alters the backbone mobility of intestinal fatty acid binding protein as monitored by 15N NMR relaxation and 1H exchange. Biochemistry 1997, 36:2278–2290. DOI: 10.1021/bi962018l
35. Russell DW, Setchell KD: Bile acid biosynthesis. Biochemistry 1992, 31:4737–4749. DOI: 10.1021/bi00135a001
36. Cheema SK, Cikaluk D, Agellon LB: Dietary fats modulate the regulatory potential of dietary cholesterol on cholesterol 7a-hydroxylase gene expression. J Lipid Res 1997 38:315–323.
37. Cohen JC, Cali JJ, Jelinek DF, et al.: Cloning of the human cholesterol 7a-hydroxylase gene (CYP7) and localization t chromosome 8q11–q12. Genomics 1992, 14:153–161. DOI: 10.1016/S0888-7543(05)80298-8
38. Wang J, Freeman DJ, Grundy SM, et al.: Linkage between cholesterol 7alpha-hydroxylase and high plasma low density lipoprotein cholesterol concentrations. J Clin Invest 1998, 101:1283–1291. DOI: 10.1172/JCI1343
39. Molowa DT, Chen WS, Cimis GM, Tan CP: Transcriptional regulation of the human cholesterol 7 alpha-hydroxylase gene. Biochemistry 1992, 31:2539–2544. DOI: 10.1021/bi00124a014
40. Schwarz M, Russell DW, Dietschy JM, Turley SD: Marked reduction in bile acid synthesis in cholesterol 7alpha-hydroxylase-deficient mice does not lead to diminished tissue cholesterol turnover or to hypercholesterolemia. J Lipid Res 1998, 39:1833–1843.
41. Mahaney MC, Blangero J, Rainwater DL, et al.: Pleiotropy and genotype by diet interaction in a baboon model for atherosclerosis: a multivariate quantitative genetic analysis of HDL subfractions in two dietary environments. Arterioscler Thromb Vasc Biol 1999, 19:1134–1141.
42. Ordovas JM, Cassidy DK, Civeira F, et al.: Familial apolipoprotein A-I, C-III and A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11. J Biol Chem 1989, 264:16339–16342.
43. Mata P, Ordovas JM, Lopez-Miranda J, et al.: ApoA-IV phenotype affects diet-induced plasma LDL cholesterol lowering. Arterioscler Thromb 1994, 14:884–891.
44. Jansen S, Lopez-Miranda J, Ordovas JM, et al.: Effect of 360His mutation in apolipoprotein A-IV on plasma HDL-cholesterol response to dietary fat. J Lipid Res 1997, 38:1995–2002.
45. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG: Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 1999, 99:2901–2907.
46. Gerdes C, Fisher RM, Nicaud V, et al.: Lipoprotein lipase variants D9N and N291S are associated with increased plasma triglyceride and lower high-density lipoprotein cholesterol concentrations: studies in the fasting and the postprandial states: the European Atherosclerosis Research Studies. Circulation 1997, 96:733–740.
47. Reymer PW, Groenemeyer BE, Gagne E, et al.: A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidemia. Hum Mol Genet 1995, 4:1543–1549. DOI: 10.1093/hmg/4.9.1543
48. Jukema JW, Van Boven AJ, Groenemeijer B, et al.: The Asp9 Asn mutation in the lipoprotein lipase gene is associate with increased progression of coronary atherosclerosis. Circulation 1996, 94:1913–1918.
49. Wittrup HH, Tybjaerg-Hansen A, Steffensen R, et al.: Mutations in the lipoprotein lipase gene associated with ischemic heart disease in men: the Copenhagen city heart study. Arterioscler Thromb Vasc Biol 1999, 19:1535–1540.
50. Kastelein JJ, Groenemeyer BE, Hallman DM, et al.: The Asn9 variant of lipoprotein lipase is associated with the -93G promoter mutation and an increased risk of coronary artery disease. The Regress Study Group. Clin Genet 1998, 53:27–33. DOI: 10.1034/j.1399-0004.1998.531530106.x
51. Wittekoek ME, Pimstone SN, Reymer PW, et al.: A common mutation in the lipoprotein lipase gene (N291S) alters lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolemia. Circulation 1998, 97:729–735.
52. Gagne E, Genest J Jr, Zhang H, et al.: Analysis of DNA changes in the LPL gene in patients with familial combined hyperlipidemia. Arteriosclero Thromb 1994, 14:1250–1257.
53. Stocks J, Thorn JA, Galton DJ: Lipoprotein lipase genotypes for a common premature termination codon mutation detected by PCR-mediated site-directed mutagenesis and restriction digestion. J Lipid Res 1992, 33:853–857.
54. Jemaa R, Fumeron F, Poirier O, et al.: Lipoprotein lipase gene polymorphisms: associations with myocardial infarction and lipoprotein levels, the ECTIM study. J Lipid Res 1995, 36:2141–2146.
55. Mattu RK, Needham EWA, Morgan R, et al.: DNA variants at the LPL gene locus associate with angiographically defined severity of atherosclerosis and serum lipoprotein levels in a Welsh population. Arterioscler Thromb 1994, 14:1090–1097.
56. Salah D, Bohnet K, Gueguen R, et al.: Combined effects of lipoprotein lipase and apolipoprotein E polymorphisms on lipid and lipoprotein levels in the Stanislas cohort. J Lipid Res 1997, 38:904–912.
57. Humphries SE, Nicaud V, Margalef J, et al.: Lipoprotein lipas gene variation is associated with a paternal history of pre mature coronary artery disease and fasting and postprandial plasma triglycerides: the European Atherosclerosis Research Study (EARS). Arterioscler Thromb Vasc Biol 1998, 18:526–534.
58. Kozaki K, Gotoda T, Kawamura M, et al.: Mutational analysis of human lipoprotein lipase by carboxy-terminal truncation. J Lipid Res 1993, 34:1765–1772.
59. Talmud PJ, Hall S, Hollera S, et al.: LPL promoter-93T/G transition influences fasting and postprandial plasma triglycerides response in African-Americans and Hispanics. J Lipid Res 1998, 39:1189–1196.
60. Ostos MA, Lopez-Miranda J, Ordovas JM, et al.: Dietary fat clearance is modulated by genetic variation in apolipoprotein A-IV gene locus. J Lipid Res 1998, 39:2493–2500.
61. Fisher RM, Burke H, Nicaud V, et al.: Effect of variation in the apoA-IV gene on body mass index and fasting and postprandial lipids in the European Atherosclerosis Research Study II. J Lipid Res 1999, 40:287–294.
62. Agren JJ, Valve R, Vidgren H, et al.: Postprandial Lipemic response is modified by the polymorphism at codon 54 of the Fatty acid-binding protein 2 gene. Arterioscler Thromb Vasc Biol 1998, 18:1606–1610.
63. Lopez-Miranda J, Jansen S, Ordovas JM, et al.: Influence of the SstI polymorphism at the apolipoprotein C-III gene locus on the plasma low-density-lipoprotein-cholesterol response to dietary monounsaturated fat. Am J Clin Nutr 1997, 66:97–103.
64. Waterworth DM, Ribalta J, Nicaud V, et al.: ApoCIII gene variants modulate postprandial response to both glucos and fat tolerance tests. Circulation 1999, 99:1872–1877.
65. Salas J, Jansen S, Lopez-Miranda J, et al.: The SstI polymorphism of the apolipoprotein C-III gene determines the insulin response to an oral glucose tolerance test after consumption of a diet rich in saturated fats. Am J Clin Nutr 1998, 68:396–401.